高级检索
当前位置: 首页 > 详情页

Protective effect of melatonin against Adriamycin-induced cardiotoxicity

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Department of Oncology, The First Hospital of Shijiazhuang, Shijiazhuang,Hebei 050010 [2]Department of Clinical Laboratory, The First Hospital of Shijiazhuang, Shijiazhuang,Hebei 050010 [3]Department of Pharmacy, The First Hospital of Shijiazhuang, Shijiazhuang,Hebei 050010 [4]Department of Radiotherapy, The Fourth Hospital of Hebei Medical University,Shijiazhuang, Hebei 050011, P.R. China
出处:
ISSN:

关键词: melatonin Adriamycin cardiotoxicity breast cancer

摘要:
The aim of this in vivo study was to explore the protective properties of melatonin against Adriamycin-induced myocardial toxicity. A rat model of breast cancer was established and the rats were randomly divided into the blank group (Blank), the solvent group [Diss; dehydrated alcohol: physiological saline (1:9)], the Adriamycin group (ADM), the melatonin group (MLT) and the melatonin + Adriamycin group (M+A). The concentrations of lipid peroxide (LPO), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in myocardial tissues were detected, the changes in myocardial tissues were observed using light microscopy and electron microscopy, and the 1-month survival rates of each group of rats were compared. Breast cancer was established in 116 rats. In the ADM group, the concentration of LPO was higher and the concentrations of SOD and GSH-Px were significantly lower than those in the blank group. In the M+A group, compared with the ADM group, the concentration of LPO was lower (P<0.05) and the concentrations of SOD and GSH-Px were higher (P<0.05). It was observed using light and electron microscopy that the myocardial injuries to the M+A group were significantly alleviated in comparison with those in the ADM group; the 1-month survival rate in the M+A group was higher than that in the ADM group. Melatonin may have a protective role in the myocardium by reducing Adriamycin-induced myocardial oxidative damage.

基金:

基金编号: 11276178

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2013]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
JCR分区:
出版当年[2013]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2024]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2024版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]Department of Oncology, The First Hospital of Shijiazhuang, Shijiazhuang,Hebei 050010
通讯作者:
通讯机构: [2]Department of Clinical Laboratory, The First Hospital of Shijiazhuang, Shijiazhuang,Hebei 050010 [*1]Department of Clinical Laboratory, The First Hospital of Shijiazhuang, Fanxi No 36, Shijiazhuang, Hebei 050011, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号